MedTrace Logo

Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin

NCT00932165 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 451

Last updated 2010-07-20

Study results available
· View outcomes & findings →

Summary

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

Conditions

  • Breast Neoplasms

Interventions

DRUG

Exemestane

Aromasin® Tablets 25mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. " The usual adult dose is 25 mg of exemestane administered orally once daily after a meal."

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2008-11-30
Completion
2008-11-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00932165 on ClinicalTrials.gov